Cardiorenal syndrome at different stages of chronic kidney disease

被引:7
作者
Tsagalis, G. [1 ]
Zerefos, S. [1 ]
Zerefos, N. [1 ]
机构
[1] Ygia Hosp, Renal Unit, Athens, Greece
关键词
heart failure; chronic kidney disease; hypertension; anemia; dialysis; inflammation;
D O I
10.1177/039139880703000703
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The central concept of the cardiorenal syndrome (CRS) is that the heart and the kidney should be regarded not solely as individual organs but rather as a dipole with multiple interconnections. The interplay between the heart and the kidney seems complex and multitactorial. cardiac output, regulation of extracellular volume, blood pressure and renal sodium handling are the major parameters that determine the crosstalk between the 2 organs. These basic parameters are controlled through mediators (renin-angiotensin system, endothelin) and the relevant antagonists (natriuretic peptides). Recently, it has been shown that the nitric oxide/reactive oxygen species balance, sympathetic nervous system activation and the presence of systemic inflammation aggravate atherosclerosis, promote structural alterations in left ventricular geometry and favor progression of renal disease. Although the prevalence of the CRS is high, major clinical trials for heart failure have only partially addressed this issue. The present review tries to dissect the role of various components of the CRS in a way that could potentially facilitate the implementation of specific therapeutic strategies. The multiple factors that participate in the pathogenesis of this syndrome are studied in detail in an effort to better understand this syndrome and address effectively its various components, since a holistic approach could (ideally) alter the syndrome's course and hence ameliorate the prognosis of the CRS.
引用
收藏
页码:564 / 576
页数:13
相关论文
共 90 条
[1]   THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION [J].
AMBROSIONI, E ;
BORGHI, C ;
MAGNANI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02) :80-85
[2]  
[Anonymous], 2001, DIABETES CARE
[3]   Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients [J].
Aoki, J ;
Ikari, Y ;
Nakajima, H ;
Mori, M ;
Sugimoto, T ;
Hatori, M ;
Tanimoto, S ;
Amiya, E ;
Hara, K .
KIDNEY INTERNATIONAL, 2005, 67 (01) :333-340
[4]   Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients [J].
Archbold, R. Andrew ;
Balami, Dauda ;
Al-Hajiri, Abdul ;
Suliman, Abdel ;
Liew, Reg ;
Cooper, Jackie ;
Ranjadayalan, Kulasegarum ;
Knight, Charles J. ;
Deaner, Andrew ;
Timmis, Adam D. .
AMERICAN HEART JOURNAL, 2006, 152 (06) :1091-1095
[5]   End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? [J].
Arici, M ;
Walls, J .
KIDNEY INTERNATIONAL, 2001, 59 (02) :407-414
[6]  
BALL SG, 1993, LANCET, V342, P821
[7]   Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].
Barnett, AH ;
Bain, SC ;
Bouter, P ;
Karlberg, B ;
Madsbad, S ;
Jervell, J ;
Mustonen, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961
[8]   Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy [J].
Berl, T ;
Hunsicker, LG ;
Lewis, JB ;
Pfeffer, MA ;
Porush, JG ;
Rouleau, JL ;
Drury, PL ;
Esmatjes, E ;
Hricik, D ;
Parikh, CR ;
Raz, I ;
Vanhille, P ;
Wiegmann, TB ;
Wolfe, BM ;
Locatelli, F ;
Goldhaber, SZ ;
Lewis, EJ .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) :542-549
[9]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[10]   Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients [J].
Bologa, RM ;
Levine, DM ;
Parker, TS ;
Cheigh, JS ;
Serur, D ;
Stenzel, KH ;
Rubin, AL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (01) :107-114